Elusive cancer-related protein captured in flight

November 04, 2019

Scientists have for the first time seen how the MYC protein, which plays a central role in cancer, binds to a key protein and controls important functions in the cell. The study, published in Nature Structural and Molecular Biology, is a collaboration between scientists at Linköping University, Sweden, and the Princess Margaret Cancer Center in Toronto, Canada. The new discovery may in the long term help in the development of new cancer drugs that disrupt the function of MYC in tumour cells.

The MYC protein regulates many important functions in healthy cells. But MYC is often extremely overactive in aggressive tumours, where its function can be likened to that of an accelerator pedal that has got stuck. The mechanisms by which MYC functions in the cell are largely unknown. The scientists who carried out the present study, therefore, wanted to find out how the transcription factor MYC interacts with another protein, the TATA-binding protein (abbreviated "TBP"). TBP acts as a starting button for the expression of many genes in the cell.

MYC, however, has proved to be elusive for structural biologists. It is what is known as a "disordered" protein, which constantly shifts between different structures in a very dynamic manner. MYC can bind to over 300 different proteins in the cell. The key to MYC being able to interact with so many other proteins so rapidly is probably its adaptability and its ability to change structure in a flash.

Around 70% of proteins implicated in cancer development are disordered proteins. If we can disturb the function of these proteins in tumour cells, we may have the basis of new treatments for cancer. But first, we must understand in detail how they function. One of the challenges facing researchers is that they must find conditions in which the MYC protein is sufficiently stable for them to examine the protein structure at atomic level. They have now managed to capture an instantaneous image of MYC bound to TBP, and been able to study the protein complex using methods such as crystallography and nuclear magnetic resonance (NMR).

"We already suspected that there was a binding site on the seat of the saddle-shaped TBP protein. But the first thing we found by crystallography was how MYC binds the concave side of the TBP 'saddle', which we weren't expecting", says Maria Sunnerhagen, professor in the Department of Physics, Chemistry and Biology at Linköping University and leader of the study.

The next step was to see whether the structure they had found played a role in the protein's biological function. The scientists created mutations of MYC in which different features of the binding site had been removed. They then investigated how the function of the protein, and how cell growth and survival, were affected.

"We have shown that both binding sites influence MYC activity and affect cell growth and proliferation. Breaking the interaction between MYC and TBP dramatically decreases the ability of the cells to survive", says Maria Sunnerhagen.

The scientists have not been able to directly image the dynamic binding site that has the greater biological function at atomic resolution yet. For this reason, they combined data from different methods and carried out advanced calculations in a supercomputer to model the interaction between the two proteins. They used AI to home in on the structure that agrees best with the observed data and in this way identified a previously unknown binding site. The researchers believe that MYC helps to increase gene expression by making it easier to place TBP at the correct location on the DNA.
Financial support for the study has been granted by, among others, the Swedish Research Council, the Carl Trygger Foundation, the Swedish Childhood Cancer Foundation, Cancerfonden, the Canadian Institutes of Health Research and the Swedish Foundation for International Cooperation in Research and Higher Education (STINT).

The article: "Multiple direct interactions of TBP with the MYC oncoprotein", Yong Wei, Diana Resetca, Zhe Li, Isak Johansson-Åkhe, Alexandra Ahlner, Sara Helander, Amelie Wallenhammar, Vivian Morad, Brian Raught, Björn Wallner, Tetsuro Kokubo, Yufeng Tong, Linda Z. Penn and Maria Sunnerhagen, (2019), Nature Structural and Molecular Biology, published online 4 November 2019, doi: 10.1038/s41594-019-0321-z

Link: http://dx.doi.org/10.1038/s41594-019-0321-z

Linköping University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.